NDC 61715-015-12 - Preferred Plus Maximum Strength Urinary Pain Relief
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 61715-015
- Requested NDC
- 61715-015-12
- Package NDCs from labels
- 61715-015-12, 61715-015-01
- Manufacturer
- Kinray | Reese Pharmaceutical Co
- Effective date
- 2019-01-30
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| PHENAZOPYRIDINE HYDROCHLORIDE - Kinray | Reese Pharmaceutical Co | Kinray | Reese Pharmaceutical Co | 2019-01-30 | HUMAN OTC DRUG LABEL |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| PHENAZOPYRIDINE HYDROCHLORIDE | ACTIVE INGREDIENT | 0EWG668W17 | PREFERRED PLUS MAXIMUM STRENGTH URINARY PAIN RELIEF (PHENAZOPYRIDINE HYDROCHLORIDE) TABLET [KINRAY] | 1 | |
| PHENAZOPYRIDINE | ACTIVE MOIETY | K2J09EMJ52 | PREFERRED PLUS MAXIMUM STRENGTH URINARY PAIN RELIEF (PHENAZOPYRIDINE HYDROCHLORIDE) TABLET [KINRAY] | 1 | |
| LACTOSE | INACTIVE INGREDIENT | J2B2A4N98G | PREFERRED PLUS MAXIMUM STRENGTH URINARY PAIN RELIEF (PHENAZOPYRIDINE HYDROCHLORIDE) TABLET [KINRAY] | 1 | |
| MAGNESIUM SILICATE | INACTIVE INGREDIENT | 9B9691B2N9 | PREFERRED PLUS MAXIMUM STRENGTH URINARY PAIN RELIEF (PHENAZOPYRIDINE HYDROCHLORIDE) TABLET [KINRAY] | 1 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| AZO | URINARY PAIN RELIEF | i-Health, Inc. | 3d0298b7-eaec-488b-9cab-19af4614ff53 | 2026-01-05 | Warnings | 0EWG668W17 |
| Phenazopyridine Hydrochloride | PHENAZOPYRIDINE | Northwind Health Company, LLC | f2f3e29f-9553-f7c3-e053-2995a90aff36 | 2026-01-01 | Adverse reactions | 0EWG668W17 |
| B03 Sinus Relief | ALLIUM CEPA, CALCAREA IODATA, CALCAREA SULPHURICA, ECHINACEA ANGUSTIFOLIA, ECHINACEA PURPUREA, EUPHORBIUM OFFICINARUM, HEPAR SULPHURIS CALCAREUM, HISTAMINUM HYDROCHLORICUM, HYDRASTIS CANADENSIS, KALI BICHROMICUM, KALI MURIATICUM, KALI SULPHURICUM, LAC DEFLORATUM, LUFFA OPERCULATA, MERCURIUS SULPHURATUS RUBER, PHOSPHORUS, PULSATILLA VULGARIS, SACCHARUM LACTIS, THUJA OCCIDENTALIS | Apex Energetics Inc. | bad83f77-e9ae-7118-e053-2a95a90aa737 | 2025-12-31 | Warnings | J2B2A4N98G |
| Maximum Strength Urinary Pain Relief | PHENAZOPYRIDINE HYDROCHLORIDE | TARGET CORPORATION | e6e27e7f-d04c-5a49-e053-2a95a90a776a | 2025-12-30 | Warnings | 0EWG668W17 |
| Vexia Maximum Strength Urinary Pain Relief | PHENAZOPYRIDINE HYDROCHLORIDE | Reese Pharmaceutical Co | 5fbc47d2-cecd-4187-9bcc-51b1d0b7695d | 2025-12-29 | Warnings | 0EWG668W17 |
| Phenazopyridine Hydrochloride | PHENAZOPYRIDINE | Northwind Health Company, LLC | f29f2ed6-6fd1-fd65-e053-2a95a90aedc4 | 2025-12-26 | Adverse reactions | 0EWG668W17 |
| PHENAZOPYRIDINE HYDROCHLORIDE | PHENAZOPYRIDINE HYDROCHLORIDE | Chartwell RX, LLC | 9ed3cf8c-e1c1-4290-b094-25ac6f7a9a56 | 2025-12-11 | Adverse reactions | 0EWG668W17 |
| Phenazopyridine Hydrochloride | PHENAZOPYRIDINE HYDROCHLORIDE | A-S Medication Solutions | d514fd31-feeb-4371-9b28-eec9834a7003 | 2025-12-10 | Warnings, Adverse reactions | 0EWG668W17 |
| Phenazopyridine Hydrochloride | PHENAZOPYRIDINE HYDROCHLORIDE | A-S Medication Solutions | cd78a132-037c-412a-9c56-e38367e05c92 | 2025-12-10 | Warnings, Adverse reactions | 0EWG668W17 |
| Quality Choice Urinary Pain Relief | PHENAZOPYRIDINE HYDROCHLORIDE | Chain Drug Marketing Association | 45e0cc2f-4a25-40ef-86ed-d1212815d751 | 2025-12-02 | Warnings | 0EWG668W17 |
| Quality Choice Maximum Strength Urinary Pain Relief | PHENAZOPYRIDINE HYDROCHLORIDE | Chain Drug Marketing Association | 3cee4fea-f1ef-4020-9b55-02b794b12820 | 2025-12-02 | Warnings | 0EWG668W17 |
| AZO Urinary Pain Relief Maximum Strength | PHENAZOPYRIDINE HYDROCHLORIDE | i-Health, Inc. | b4874fe2-d98b-4b5c-baad-d75070947842 | 2025-11-17 | Warnings | 0EWG668W17 |
| Phenazopyridine Hydrochloride | PHENAZOPYRIDINE | VERITYRX, LLC | 427b6ffb-3ff1-932f-e063-6394a90ae8b9 | 2025-10-31 | Adverse reactions | 0EWG668W17 |
| Uqora Maximum UTI Pain Relief | PHENAZOPYRIDINE HYDROCHLORIDE | Bonafide Health, LLC dba Uqora | 426317e7-a925-116a-e063-6294a90a52dc | 2025-10-27 | Warnings | 0EWG668W17 |
| Uristat Ultra | PHENAZOPYRIDINE HYDROCHLORIDE | Medtech Products Inc. | c705185f-4908-451e-993b-b0b8a73f0392 | 2025-10-23 | Warnings | 0EWG668W17 |
| Monistat Maintain | PHENAZOPYRIDINE HYDROCHLORIDE | Insight Pharmaceuticals LLC | d1e563fc-5a91-4867-8177-93102bd24fe4 | 2025-10-23 | Warnings | 0EWG668W17 |
| Sugar Cravings | CINNAMIC ACID, PHLORIDZINUM, ARGENTUM NITRICUM, ADENOSINUM TRIPHOSPHORICUM DINATRUM, BEET SUGAR, DEXTROSE, D-RIBOSE, FRUCTOSE, LYCOPODIUM CLAVATUM, MAPLE SUGAR, SACCHARUM LACTIS, SACCHARUM OFFICINALE, SARCOLACTICUM ACIDUM, MALVIN, ADRENOCORTICOTROPHIN, DYSENTERY BACILLUS, MORGAN GAERTNER | Dr. Donna Restivo DC | 401873ba-ae1b-4506-a2e8-c6c0e5ff27f5 | 2025-10-21 | Warnings | J2B2A4N98G |
| Phenazopyridine Hydrochloride | PHENAZOPYRIDINE | Bryant Ranch Prepack | 6ac0f3ce-0cc2-403c-946d-13b285ae98aa | 2025-09-19 | Adverse reactions | 0EWG668W17 |
| Phenazopyridine Hydrochloride | PHENAZOPYRIDINE | A-S Medication Solutions | d8155f91-d650-4021-91ee-f3b6c1055a36 | 2025-09-05 | Adverse reactions | 0EWG668W17 |
| Phenazopyridine Hydrochloride | PHENAZOPYRIDINE | A-S Medication Solutions | 900222e8-fc92-4d73-b3d5-1636e717bd65 | 2025-09-05 | Adverse reactions | 0EWG668W17 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.